# US 2001/0012965 A1 · In vitro production of transplantable cartilage tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0012965 A1
- Document ID: US20010012965A1
- Status: Published application
- Kind: A1
- Application number: 09/799,284
- Filed: 2001-03-05
- Published: 2001-08-09
- Earliest claimed: 1999-03-01
- Assignees: Rush-Presbyterian-St. Luke's Medical Center
- Inventors: Koichi Masuda; Eugene J-M. A. Thomar; Michael Hejna
- Web page: https://patentgrep.com/patent/US20010012965A1

## CPC

- A61L 27/3817: {Cartilage-forming cells, e.g. pre-chondrocytes}
- A61F 2/30756: {Cartilage endoprostheses (A61F2/3603 takes precedence)}
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/24: Collagen
- A61L 27/3633: {Extracellular matrix [ECM]}
- A61L 27/3654: {Cartilage, e.g. meniscus}
- A61L 27/3852: {Cartilage, e.g. meniscus}
- A61L 27/3895: {using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- C12N 5/0655: {Chondrocytes; Cartilage}
- A61F 2/3094: {Designing or manufacturing processes}
- A61F 2310/00365: Proteins; Polypeptides; Degradation products thereof
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61L 2430/06: for cartilage reconstruction, e.g. meniscus
- C12N 2500/38: Vitamins
- C12N 2531/00: Microcarriers
- C12N 2533/74: Alginate
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- Y10S 623/915: Method or apparatus for preparing biological material
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention is directed to a transplantable cartilage matrix and a method for its in vitro production.

## Claims

### Claim 1

A method for the production of transplantable cartilage matrix, the method comprising:
isolating chondrogenic cells;
culturing chondrogenic cells for an amount of time effective for allowing formation of a chondrogenic cell-associated matrix;
recovering the chondrogenic cells with the cell-associated matrix; and
culturing the chondrogenic cells with the cell-associated matrix on a semipermeable membrane in the presence of growth factor for a time effective for allowing formation of a cartilage matrix.

### Claim 2 (depends on 1)

A method for the production of transplantable cartilage matrix according to claim 1 wherein the chondrogenic cells are cultured in an alginate medium.

### Claim 3 (depends on 1)

A method for the production of transplantable cartilage matrix according to claim 1 wherein the chondrogenic cell-associated matrix includes aggrecan, collagen types II, IX and XI, and hyaluronan.

### Claim 4 (depends on 3)

A method for the production of transplantable cartilage matrix according to claim 3 wherein the ratio aggregan to hyaluronan in the chondrogenic cell-associated matrix is at least above about 10:1.

### Claim 5 (depends on 1)

A method for the production of transplantable cartilage matrix according to claim 1 wherein the semipermeable membrane has a pore size of less than about 5 microns and a pore density of at least about 8×105 pores per cm2.

### Claim 6 (depends on 1)

A method for the production of transplantable cartilage matrix according to claim 1 wherein the growth factor is selected from the group consisting of osteogenic protein-1, bone morphogenetic proteins, transforming growth factor beta, insulin-like growth factor, and mixtures thereof.

### Claim 7 (depends on 1)

A method for the production of transplantable cartilage matrix according to claim 1 wherein the cartilage matrix includes aggrecan, collagen types II, IX and XI, and hyaluronan.

### Claim 8 (depends on 7)

A method for the production of transplantable cartilage matrix according to claim 7 wherein the cartilage matrix has a ratio aggregan to hyaluronan of at least above about 10:1.

### Claim 9

A cohesive carilage matrix produced by a method comprising:
isolating chondrogenic cells;
culturing chondrogenic cells for an amount of time effective for allowing formation of a chondrogenic cell-associated matrix;
recovering the chondrogenic cells with the cell-associated matrix; and
culturing the chondrogenic cells with the cell-associated matrix on a semipermeable membrane in the presence of growth factor for a time effective for allowing formation of a cohesive cartilage matrix.

### Claim 10 (depends on 9)

A cohesive cartilage matrix according to claim 9 wherein the chondrogenic cells are cultured in an alginate medium.

### Claim 11 (depends on 9)

A cohesive cartilage matrix according to claim 9 wherein the chondrogenic cell-associated matrix includes aggrecan, collagen types II, IX and XI, and hyaluronan.

### Claim 12 (depends on 11)

A cohesive cartilage matrix according to claim 11 wherein the ratio aggregan to hyaluronan in the chondrogenic cell-associated matrix is at least above about 10:1.

### Claim 13 (depends on 9)

A cohesive cartilage matrix according to claim 9 wherein the semipermeable membrane has a pore size of less than about 5 microns and a pore density of at least about 8×105 pores per cm2.

### Claim 14 (depends on 9)

A cohesive cartilage matrix according to claim 9 wherein the growth factor is selected from the group consisting of osteogenic protein-1, bone morphogenetic proteins, transforming growth factor beta, insulin-like growth factor, and mixtures thereof.

### Claim 15 (depends on 9)

A cohesive cartilage matrix according to claim 9 wherein the cohesive cartilage matrix includes aggrecan, collagen types II, IX and XI, and hyaluronan.

### Claim 16 (depends on 15)

A cohesive cartilage matrix according to claim 15 wherein the cohesive cartilage matrix has a ratio aggregan to hyaluronan of at least above about 10:1.

### Claim 17

A cohesive cartilage matrix comprising:
at least about 5 mg/cc3 aggrecan;
collagen types II, IX and XI, and hyaluronan; wherein the ratio of aggrecan to hyaluronan is about 10:1 to about 200:1, and the ratio of aggrecan to collagen is about 1:1 to about 10:1.

### Claim 18 (depends on 17)

A cohesive cartilage matrix according to claim 17 wherein the matrix has a thickness of less than about 2 mm.

### Claim 19

A method for the surgical repair of cartilage damage comprising:
producing a transplantable cartilage matrix; and
surgically implanting the cartilage matrix.

### Claim 20 (depends on 19)

A method for the surgical repair of cartilage damage according to claim 19 wherein the transplantable cartilage matrix is produced by a method comprising:
isolating chondrogenic cells;
culturing chondrogenic cells for an amount of time effective for allowing formation of a chondrogenic cell-associated matrix;
recovering the chondrogenic cells with the cell-associated matrix;
culturing the chondrogenic cells with the cell-associated matrix on a semipermeable membrane in the presence of growth factor for a time effective for allowing formation of a cartilage matrix.

### Claim 21 (depends on 20)

A method for the surgical repair of cartilage damage according to claim 20 wherein the chondrogenic cells are cultured in an alginate medium.

### Claim 22 (depends on 20)

A method for the surgical repair of cartilage damage according to claim 20 wherein the chondrogenic cell-associated matrix includes aggrecan, collagen types II, IX and XI, and hyaluronan.

### Claim 23 (depends on 22)

A method for the surgical repair of cartilage damage according to claim 22 wherein the ratio aggregan to hyaluronan in the chondrogenic cell-associated matrix is at least above about 10:1.

### Claim 24 (depends on 20)

A method for the surgical repair of cartilage damage according to claim 20 wherein wherein the semipermeable membrane has a pore size of less than about 5 microns and a pore density of at least about 8×105 pores per cm2.

### Claim 25 (depends on 20)

A method for the surgical repair of cartilage damage according to claim 20 wherein wherein the growth factor is selected from the group consisting of osteogenic protein-1, bone morphogenetic proteins, transforming growth factor beta, insulin-like growth factor, and mixtures thereof.

### Claim 26 (depends on 19)

A method for the surgical repair of cartilage damage according to claim 19 wherein the cartilage matrix includes aggrecan, collagen types II, IX and XI, and hyaluronan.

### Claim 27 (depends on 26)

A method for the production of transplantable cartilage matrix according to claim 26 wherein the cartilage matrix has a ratio aggregan to hyaluronan of at least above about 10:1.
